An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)
Phase 2
Completed
- Conditions
- InfectionsPelvic Infections
- Registration Number
- NCT00092170
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections.
- Detailed Description
The duration of treatment is 18 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients aged 3 months to 17 years with intra-abdominal infection or acute pelvic infection
Exclusion Criteria
- Immune problems
- Kidney problems
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy response at post treatment follow up assessment. Clinical and/or laboratory drug-related SAEs during study drug therapy plus 14 days post therapy
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ertapenem's efficacy in treating complicated intra-abdominal infections in pediatrics?
How does ertapenem sodium compare to ticarcillin/clavulanate in managing acute pelvic infections in children?
Which biomarkers correlate with clinical response to ertapenem in pediatric sepsis models?
What adverse events were observed in NCT00092170 pediatric ertapenem trials and how were they managed?
Are there synergistic combination therapies with ertapenem for hospital-acquired pneumonia in adolescents?